Cargando…

Antibiotic-Eluting Envelopes to Prevent Cardiac-Implantable Electronic Device Infection: Past, Present, and Future

Objective: Cardiac-implantable electronic device (CIED) infections are associated with significant morbidity and mortality. In this review, we describe the risk factors and pathogenesis of CIED infections and review the rationale and the evidence for the use of antibiotic-eluting envelopes (ABEs) in...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiang, Kun, Catanzaro, John N, Elayi, Claude, Esquer Garrigos, Zerelda, Sohail, Muhammad R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7948693/
https://www.ncbi.nlm.nih.gov/pubmed/33728111
http://dx.doi.org/10.7759/cureus.13088
_version_ 1783663440975364096
author Xiang, Kun
Catanzaro, John N
Elayi, Claude
Esquer Garrigos, Zerelda
Sohail, Muhammad R
author_facet Xiang, Kun
Catanzaro, John N
Elayi, Claude
Esquer Garrigos, Zerelda
Sohail, Muhammad R
author_sort Xiang, Kun
collection PubMed
description Objective: Cardiac-implantable electronic device (CIED) infections are associated with significant morbidity and mortality. In this review, we describe the risk factors and pathogenesis of CIED infections and review the rationale and the evidence for the use of antibiotic-eluting envelopes (ABEs) in patients at increased risk for CIED infections. Findings: The majority of CIED infections are caused by staphylococci that involve generator pocket and occur due to contamination of the device or the pocket tissues at the time of implantation. Clinical trials have shown that extending the duration of post-operative systemic antibacterial therapy is not beneficial in reducing CIED infection rate. However, ABEs that reduce device migration after implantation and provide sustained local delivery of prophylactic antibiotics at the pocket site, may provide benefit in reducing infection. Currently, there are two types of commercially available CIED envelope devices in the United States. The first ABE device (TYRX™, Medtronic Inc., Monmouth Junction, NJ) is composed of a synthetic absorbable mesh envelope that elutes minocycline and rifampin and has been shown to reduce CIED pocket infections in a large multi-center randomized clinical trial. The second ABE device (CanGaroo-G™, Aziyo Biologics, Silver Spring, MD) is composed of decellularized extracellular matrix (ECM) and was originally designed to stabilize the device within the pocket, limiting risk for migration or erosion, and providing a substrate for tissue ingrowth in a preclinical study. This device has shown promising results in a preclinical study with local delivery of gentamicin. Compared with artificial materials, such as synthetic surgical mesh, biologic ECM has been shown to foster greater tissue integration and vascular ingrowth, a reduced inflammatory response, and more rapid clearance of bacteria. Conclusions and Relevance: ABE devices provide sustained local delivery of antibiotics at the generator pocket site and appear beneficial in reducing CIED pocket infections. Given the continued increase in the use of CIED therapy and resultant infectious complications, innovative approaches to infection prevention are critical.
format Online
Article
Text
id pubmed-7948693
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-79486932021-03-15 Antibiotic-Eluting Envelopes to Prevent Cardiac-Implantable Electronic Device Infection: Past, Present, and Future Xiang, Kun Catanzaro, John N Elayi, Claude Esquer Garrigos, Zerelda Sohail, Muhammad R Cureus Cardiology Objective: Cardiac-implantable electronic device (CIED) infections are associated with significant morbidity and mortality. In this review, we describe the risk factors and pathogenesis of CIED infections and review the rationale and the evidence for the use of antibiotic-eluting envelopes (ABEs) in patients at increased risk for CIED infections. Findings: The majority of CIED infections are caused by staphylococci that involve generator pocket and occur due to contamination of the device or the pocket tissues at the time of implantation. Clinical trials have shown that extending the duration of post-operative systemic antibacterial therapy is not beneficial in reducing CIED infection rate. However, ABEs that reduce device migration after implantation and provide sustained local delivery of prophylactic antibiotics at the pocket site, may provide benefit in reducing infection. Currently, there are two types of commercially available CIED envelope devices in the United States. The first ABE device (TYRX™, Medtronic Inc., Monmouth Junction, NJ) is composed of a synthetic absorbable mesh envelope that elutes minocycline and rifampin and has been shown to reduce CIED pocket infections in a large multi-center randomized clinical trial. The second ABE device (CanGaroo-G™, Aziyo Biologics, Silver Spring, MD) is composed of decellularized extracellular matrix (ECM) and was originally designed to stabilize the device within the pocket, limiting risk for migration or erosion, and providing a substrate for tissue ingrowth in a preclinical study. This device has shown promising results in a preclinical study with local delivery of gentamicin. Compared with artificial materials, such as synthetic surgical mesh, biologic ECM has been shown to foster greater tissue integration and vascular ingrowth, a reduced inflammatory response, and more rapid clearance of bacteria. Conclusions and Relevance: ABE devices provide sustained local delivery of antibiotics at the generator pocket site and appear beneficial in reducing CIED pocket infections. Given the continued increase in the use of CIED therapy and resultant infectious complications, innovative approaches to infection prevention are critical. Cureus 2021-02-02 /pmc/articles/PMC7948693/ /pubmed/33728111 http://dx.doi.org/10.7759/cureus.13088 Text en Copyright © 2021, Xiang et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Cardiology
Xiang, Kun
Catanzaro, John N
Elayi, Claude
Esquer Garrigos, Zerelda
Sohail, Muhammad R
Antibiotic-Eluting Envelopes to Prevent Cardiac-Implantable Electronic Device Infection: Past, Present, and Future
title Antibiotic-Eluting Envelopes to Prevent Cardiac-Implantable Electronic Device Infection: Past, Present, and Future
title_full Antibiotic-Eluting Envelopes to Prevent Cardiac-Implantable Electronic Device Infection: Past, Present, and Future
title_fullStr Antibiotic-Eluting Envelopes to Prevent Cardiac-Implantable Electronic Device Infection: Past, Present, and Future
title_full_unstemmed Antibiotic-Eluting Envelopes to Prevent Cardiac-Implantable Electronic Device Infection: Past, Present, and Future
title_short Antibiotic-Eluting Envelopes to Prevent Cardiac-Implantable Electronic Device Infection: Past, Present, and Future
title_sort antibiotic-eluting envelopes to prevent cardiac-implantable electronic device infection: past, present, and future
topic Cardiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7948693/
https://www.ncbi.nlm.nih.gov/pubmed/33728111
http://dx.doi.org/10.7759/cureus.13088
work_keys_str_mv AT xiangkun antibioticelutingenvelopestopreventcardiacimplantableelectronicdeviceinfectionpastpresentandfuture
AT catanzarojohnn antibioticelutingenvelopestopreventcardiacimplantableelectronicdeviceinfectionpastpresentandfuture
AT elayiclaude antibioticelutingenvelopestopreventcardiacimplantableelectronicdeviceinfectionpastpresentandfuture
AT esquergarrigoszerelda antibioticelutingenvelopestopreventcardiacimplantableelectronicdeviceinfectionpastpresentandfuture
AT sohailmuhammadr antibioticelutingenvelopestopreventcardiacimplantableelectronicdeviceinfectionpastpresentandfuture